Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Transaction Price: £16.6781 per share
- Transaction Volume: 30.955 shares
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of ordinary shares by Mr. R G Connor, President of Global Manufacturing & Supply, following the re-investment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of an insider transaction executed on the London Stock Exchange.
Investor Verification Points
- Verify the dividend reinvestment policy and the specific dividend payment date of July 14, 2016.
- Confirm the share price of £16.6781 against market data for July 14, 2016.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive metrics.